title: Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma.
abstract: OBJECTIVE
  To verify the short-term influence of an orally administered nonsteroidal anti-inflammatory drug on the intraocular pressure (IOP) of primary open-angle glaucoma patients in therapy with a topical prostaglandin analog.
  
  
  METHODS
  Randomized cross-over double-blind study.
  
  
  METHODS
  Sixteen adults with primary open-angle glaucoma, receiving 0.005% latanoprost eyedrops once daily, were treated with a single dose of either 100 mg nimesulide or placebo. IOP was recorded at baseline and at 1, 2, 4, 8, 12, and 24 hours.
  
  
  RESULTS
  After nimesulide administration, there was a decrease in IOP (with a fall at the second hour, P<.01) that remained significant 8 hours later (P<.05). At 12 and 24 hours, there were unremarkable IOP differences between the two regimens.
  
  
  CONCLUSIONS
  In patients with primary open-angle glaucoma, single-dose nimesulide significantly enhances the latanoprost-induced IOP-lowering effects during the short plasma half-life of this non-steroidal anti-inflammatory drug.
authors.affiliation: Department of Ophthalmology, University of Ferrara, and Neuro-ophthalmology and Ocular Immunology Service, Magenta and Abbiategrasso General Hospital, Italy.
authors.forename: Ciro
authors.initials: C
authors.lastname: Costagliola
authors.forename: Francesco
authors.initials: F
authors.lastname: Parmeggiani
authors.forename: Antonio
authors.initials: A
authors.lastname: Caccavale
authors.forename: Adolfo
authors.initials: A
authors.lastname: Sebastiani
mesh_terms: D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage*; D014065:Tonometry, Ocular
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D013449:Sulfonamides; D000077338:Latanoprost; C012655:nimesulide